Madhav V Dhodapkar

List of Publications by Citations

75 papers	3,208 citations	29 h-index	56 g-index
83 ext. papers	4,030 ext. citations	6.1 avg, IF	5.49 L-index

#	Paper	IF	Citations
75	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. *OncoImmunology*, **2016**, 5, e1071008	7.2	367
74	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
73	Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. *Journal of Immunology*, **2015**, 194, 950-9	5.3	269
72	Natural Killer T Cells in Cancer Immunotherapy. *Frontiers in Immunology*, **2017**, 8, 1178	8.4	130
71	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. *Blood*, **2008**, 112, 1308-16	2.2	118
70	Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. *New England Journal of Medicine*, **2016**, 374, 555-61	59.2	117
69	Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. *Journal of Experimental Medicine*, **2007**, 204, 1359-69	16.6	117
68	Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538	7.2	101
67	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. *JCI Insight*, **2018**, 3,	9.9	90
66	Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. *Blood*, **2015** , 125, 1256-71	2.2	89
65	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. *JCI Insight*, **2016**, 1, e88955	9.9	86
64	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. *Nature Medicine*, **2016**, 22, 1351-1357	50.5	86
63	MGUS to myeloma: a mysterious gammopathy of underexplored significance. *Blood*, **2016**, 128, 2599-2606	2.2	83
62	Precancer Atlas to Drive Precision Prevention Trials. *Cancer Research*, **2017**, 77, 1510-1541	10.1	81
61	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. *Blood*, **2015**, 125, 4042-51	2.2	78
60	Targeting human dendritic cells in situ to improve vaccines. *Immunology Letters*, **2014**, 162, 59-67	4.1	74
59	Type II NKT Cells and Their Emerging Role in Health and Disease. *Journal of Immunology*, **2017**, 198, 1015-1021	5.3	64

58	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. *Blood Cancer Journal*, **2019**, 9, 94	7	59
57	Daratumumab in multiple myeloma. *Cancer*, **2019**, 125, 2364-2382	6.4	58
56	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1928-1937	2.2	56
55	Trial watch: Dendritic cell-based anticancer therapy. *OncoImmunology*, **2014**, 3, e963424	7.2	54
54	ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. *Journal of Clinical Investigation*, **2016**, 126, 3905-3916	15.9	52
53	Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. *Blood*, **2009**, 113, 793-6	2.2	51
52	Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. *Clinical Immunology*, **2011**, 140, 160-6	9	43
51	Conditional overexpression of TGFβ1 promotes pulmonary inflammation, apoptosis and mortality via TGFβR2 in the developing mouse lung. *Respiratory Research*, **2015**, 16, 4	7.3	42
50	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. *Frontiers in Immunology*, **2018**, 9, 2204	8.4	36
49	Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. *Journal of Immunology*, **2014**, 193, 2297-305	5.3	35
48	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 1541-1554	12.9	35
47	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). *Haematologica*, **2015**, 100, 1214-21	6.6	34
46	Antigen-mediated regulation in monoclonal gammopathies and myeloma. *JCI Insight*, **2018**, 3,	9.9	28
45	Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. *Frontiers in Bioscience - Landmark*, **2009**, 14, 796-807	2.8	27
44	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 296-304.e2	2	24
43	Immunity to stemness genes in human cancer. *Current Opinion in Immunology*, **2010**, 22, 245-50	7.8	24
42	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. *British Journal of Haematology*, **2018**, 182, 495-503	4.5	23
41	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. *Cancer*, **2019**, 125, 416-423	6.4	22

40	Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).. *Journal of Clinical Oncology*, **2020**, 38, 8507-8507	2.2	18
39	Systematic evaluation of immune regulation and modulation **2017**, 5, 21		15
38	Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. *Molecular Genetics and Metabolism*, **2020**, 129, 286-291	3.7	15
37	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 537-544	2	15
36	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia **2016**, 4, 90		14
35	Vaccines targeting cancer stem cells: are they within reach?. *Cancer Journal (Sudbury, Mass)*, **2011**, 17, 397-402	2.2	13
34	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. *JCI Insight*, **2020**, 5,	9.9	13
33	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. *Journal of Clinical Oncology*, **2019**, 37, 8001-8001	2.2	13
32	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma **2020**, 8,		13
31	MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. *Blood*, **2018**, 131, 2500-2501	2.2	12
30	Role of chaperones and FcgammaR in immunogenic death. *Current Opinion in Immunology*, **2008**, 20, 512-18	7.8	12
29	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. *Blood Cancer Discovery*, **2021**, 2, 9-12	7	11
28	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. *Blood*, **2021**, 137, 3604-3615	2.2	11
27	Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges. *Cancer Immunology, Immunotherapy*, **2011**, 60, 413-8	7.4	10
26	Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?. *Cancer Prevention Research*, **2013**, 6, 173-6	3.2	6
25	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 7944-5	11.5	6
24	Hematologic Malignancies: Plasma Cell Disorders. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 561-568	7.1	5
23	Risk-associated alterations in marrow T cells in pediatric leukemia. *JCI Insight*, **2020**, 5,	9.9	5

22	Tissue-resident memory-like T cells in tumor immunity: Clinical implications. *Seminars in Immunology*, **2020**, 49, 101415	10.7	5
21	Game of Bones: How Myeloma Manipulates Its Microenvironment. *Frontiers in Oncology*, **2020**, 10, 625199	5.3	5
20	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.. *Journal of Clinical Oncology*, **2022**, JCO2200088	2.2	4
19	Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?. *Frontiers in Immunology*, **2019**, 10, 2385	8.4	3
18	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. *American Journal of Hematology*, **2021**, 96, E68-E71	7.1	3
17	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. *Leukemia*, **2021**,	10.7	3
16	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.. *Journal of Clinical Oncology*, **2022**, JCO2102257	2.2	3
15	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. *Blood*, **2018**, 132, 3294-3294	2.2	2
14	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. *Blood*, **2013**, 122, 3174-3174	2.2	2
13	A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).. *Journal of Clinical Oncology*, **2017**, 35, TPS8053-TPS8053	2.2	2
12	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. *Blood Cancer Discovery*, **2021**, 2, 600-615	7	2
11	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. *Blood*, **2018**, 132, 3241-3241	2.2	1
10	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. *Blood*, **2012**, 120, 4079-4079	2.2	1
9	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. *Blood*, **2015**, 126, 120-120	2.2	1
8	Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. *Blood*, **2015**, 126, 3058-3058	2.2	1
7	Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. *Blood*, **2016**, 128, 2139-2139	2.2	1
6	Safety and Efficacy of Evomela® in Myeloma Autotransplants. *Blood*, **2018**, 132, 3446-3446	2.2	0
5	Reply to N. Biran et al. *Journal of Clinical Oncology*, **2020**, 38, 1368-1369	2.2	

4	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. *Blood*, **2018**, 132, 3302-3302	2.2
3	Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. *Blood*, **2012**, 120, 2933-2933	2.2
2	Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study. *Blood*, **2012**, 120, 4944-4944	2.2
1	Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS). *Blood*, **2012**, 120, 198-198	2.2